MTOR and Parkinson disease: CaMKs coordinated with mTOR pathway-related gene expression and improved UCH-L1 level to favor for tyrosine hydroxylase and clear abnormal α-synuclein, thereby delaying neurodegeneration or improving the pathogenesis of PD lesions.